Moreover, the SURPASS-CVOT [121,122] and TREASURE-CKD trials are investigating the benefits of tirzepatide, which provides dual GIP and GLP1 receptor activation, offering enhanced benefits in glycemic control, weight reduction, and organ protection compared to GLP1-RA monotherapy. Here, GCG is linked to chronic kidney disease.